Hypersensitivity Pneumonitis

USMLE Step 1 trap: Misclassifies HP as IgE-mediated (type I) rather than immune complex and T-cell mediated (types III/IV). HP is primarily a type III (immune complex) and type IV (delayed, T-cell mediated) hypersensitivity reaction to inhaled organic antigens.

Hypersensitivity pneumonitis (HP) is an inflammatory lung disease caused by repeated inhalation of organic antigens — think farmer's lung from moldy hay, bird fancier's lung from avian proteins, or hot tub lung from Mycobacterium avium in aerosolized water. The immune response involves both immune complex deposition (type III) and T-cell mediated inflammation (type IV), producing granulomatous interstitial pneumonitis. USMLE Step 1 tests this mostly through antigen-exposure vignettes where you need to identify the mechanism and differentiate acute from chronic presentations.

The exam loves to present an occupational or hobby history — someone who works with birds, grain, or hot tubs — then ask you to identify the immunologic mechanism or predict the clinical course. The key angles are mechanism (types III/IV, not IgE), presentation (acute flu-like vs. chronic fibrotic), and management (antigen removal first, steroids second). Students who've memorized this as 'a hypersensitivity reaction' without pinning down which type will get burned by mechanism questions.

The trickiest part is the acute-vs-chronic distinction. Acute HP looks almost infectious — fever, chills, myalgias 4–8 hours after exposure — and is fully reversible with antigen removal. Chronic HP is a different beast: progressive dyspnea, restrictive pattern on PFTs, and fibrosis on HRCT that may not reverse even if you pull the antigen. USMLE Step 1 will test whether you understand that these aren't just two severities of the same process — they have meaningfully different prognoses and management implications.

From real student decks

59%have cards covering this topic

46%have mature cards

Common misconceptions

Common mistake

Wrong: Hypersensitivity pneumonitis is a type I (IgE-mediated) hypersensitivity reaction.

Right: HP is primarily a type III (immune complex) and type IV (delayed, T-cell mediated) hypersensitivity reaction to inhaled organic antigens.

HP is not IgE-mediated, so it does not involve mast cell degranulation, eosinophilia, or the rapid wheal-and-flare response characteristic of type I reactions. Instead, inhaled organic antigens trigger immune complex deposition in alveolar walls (type III) and activate CD4+ Th1 and CD8+ T cells that drive granuloma formation (type IV). Practically speaking: HP patients don't respond to antihistamines, don't have elevated IgE, and the timeline — symptoms peaking 4–8 hours after exposure, not seconds — reflects the immune complex and delayed-type kinetics.

Common mistake

Wrong: Chronic HP always shows the same reversible flu-like symptoms as acute HP.

Right: Acute HP presents with reversible flu-like symptoms 4–8 hours after exposure, while chronic HP presents with progressive dyspnea and fibrosis that may be irreversible even after antigen removal.

Acute HP mimics a flu or pneumonia (fever, chills, dyspnea within hours of exposure) and fully resolves when the antigen is removed — the inflammation is reversible at this stage. Chronic HP results from low-level or repeated antigen exposure over months to years, leading to fibroblast activation and structural remodeling of the lung parenchyma; by the time fibrosis is established on HRCT, antigen removal may halt progression but cannot restore lost lung architecture. Treating these as the same entity will cause you to underestimate prognosis in chronic cases and miss the irreversibility angle the exam tests.

Common mistake

Gap: Underestimates antigen avoidance as the primary intervention in HP, over-relying on corticosteroids alone

Antigen avoidance is the cornerstone of HP management; corticosteroids accelerate recovery in acute HP but do not prevent progression to fibrosis if antigen exposure continues.

Corticosteroids reduce inflammation and speed symptomatic recovery in acute HP, but they do not address the underlying antigenic trigger — so if the patient keeps inhaling the offending antigen, fibrotic progression continues regardless of steroid use. Antigen avoidance is the only intervention that interrupts the disease at its source; in practice, this may mean changing occupations, removing birds from the home, or remediating water sources. The exam will distinguish students who treat HP like asthma (steroids as primary therapy) from those who understand that source control is the cornerstone of management.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Identify the correct immunologic mechanism of HP: type III (immune complex) and type IV (T-cell mediated) hypersensitivity — not IgE-mediated type I — and match classic antigens to their clinical scenarios (e.g., thermophilic actinomycetes in farmer's lung, avian proteins in bird fancier's lung).
Distinguish acute HP (reversible flu-like illness appearing 4–8 hours after antigen exposure) from chronic HP (progressive dyspnea, restrictive physiology, and potentially irreversible pulmonary fibrosis seen on HRCT as honeycombing or traction bronchiectasis).
Select the appropriate management strategy based on disease acuity: antigen avoidance is the essential first-line intervention for all forms of HP, with corticosteroids used as adjuncts in acute disease to accelerate recovery — but steroids alone without antigen removal do not prevent fibrotic progression.

Can you avoid these mistakes?

A 55-year-old farmer develops fever, chills, and dyspnea 6 hours after working with moldy hay. Symptoms resolve over 48 hours without treatment. What immunologic mechanism underlies this reaction, and how does the timeline help you distinguish it from a type I hypersensitivity response?

A 62-year-old bird breeder presents with 2 years of progressive exertional dyspnea and a dry cough. HRCT shows honeycombing and traction bronchiectasis in the upper lobes. She removes her birds from the home. Should you expect her lung function to normalize? What additional therapy is indicated?

A question stem describes a patient with HP who is started on high-dose prednisone but continues working in the same environment. Why will this management strategy likely fail, and what is the single most important intervention you should add?

You see two patients with HP: one with acute flu-like episodes that resolve between exposures, and one with persistent dyspnea and a restrictive pattern on PFTs. Which patient is more likely to have irreversible lung damage, and what HRCT findings would support that concern?

Hypersensitivity Pneumonitis

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics